Kidney Week Educational Symposia-Novel Therapeutic Options in Hyperkalemia

Video Transcription

Video Summary

The symposium reviews hyperkalemia as a common, potentially fatal electrolyte disorder in CKD and cardiovascular patients, while emphasizing uncertainty about optimal management of mild or chronic cases without ECG changes. Dr. Gary Yee describes potassium physiology and why risk varies by phenotype: mortality risk rises in a U-shaped fashion, with the highest vulnerability in patients with combined heart failure, CKD, and diabetes. An illustrative case (type 1 diabetes, AKI, ACE inhibitor, beta-blocker, digoxin, trimethoprim, low-sodium intake, vomiting) demonstrates multifactorial causes: impaired renal excretion, RAAS suppression, ENaC blockade, acidemia/hypertonicity, and reduced distal sodium delivery. He reviews renal potassium handling, type 4 RTA mechanisms, and medication contributors (RAAS inhibitors, MRAs, NSAIDs, trimethoprim). Mild–moderate hyperkalemia is often not immediately lethal but is costly, recurrent, and linked to complications; severe hyperkalemia requires urgent treatment without undue panic.<br /><br />Dr. Faiz Zannad summarizes newer potassium binders: patiromer (calcium exchange; drug-spacing issues; possible hypomagnesemia) and sodium zirconium cyclosilicate/ZS-9 (sodium exchange; faster onset; edema/hypertension concerns). Trials show both effectively lower and maintain potassium for up to a year and can enable continuation or up-titration of RAAS inhibitors/MRAs (e.g., spironolactone) in HF, CKD, resistant hypertension, and dialysis populations. Key evidence gaps remain: whether these agents improve hard clinical outcomes, reduce hospitalizations, lower costs, or allow dietary potassium liberalization; ongoing studies (e.g., DIAMOND) aim to answer this.

Asset Subtitle

Niraj Desai, Jerry Yee, Faiez Zannad
Support is provided by an educational grant from AstraZeneca Pharmaceuticals.

Keywords

hyperkalemia

chronic kidney disease (CKD)

heart failure

RAAS inhibitors (ACEi/ARB)

potassium binders (patiromer, sodium zirconium cyclosilicate)

type 4 renal tubular acidosis

medication-induced hyperkalemia (NSAIDs, trimethoprim, MRAs)

DIAMOND trial and clinical outcomes